ARI103094-Follow-Up Study for REDUCE Study Subjects
Sponsor: GlaxoSmithKline
A observational or N/A phase clinical study on Neoplasms, Prostate, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 13 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
13 versions recorded-
Oct 2025 — Present [monthly]
Completed
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
▶ Show 8 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Feb 2017 — Aug 2017 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichach, Germany, Alava, Spain, Albany, United States, Alcala de Henares (Madrid), Spain, Amsterdam, Netherlands, Anaheim, United States, Anchorage, United States, Annapolis, United States, Arnhem, Netherlands, Athens, Greece and 229 more location s